AllaChem completes phase 1a clinical study with AV4025, an HCV NS5A inhibitor

October 7 , 2013. AllaChem, LLC, announced today a successful completion of phase 1a clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. In a double-blind, placebo-controlled, single ascending oral dose study of AV4025 safety and tolerability in healthy volunteers, each dose cohort (10...

Read More

Alla Chem, LLC Announces the Completion of Pre-Clinical Studies With ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate and Breast Cancers

Hallandale Beach, Fl – July 28, 2013 – Alla Chem, LLC announced today the completion of pre-clinical studies with ONC1-13B, a next in-class small molecule androgen receptor inhibitor for the treatment of prostate and breast cancers. The results will be reported at the 3rd World Congress on Cancer Science & Therapy, October 21-23, 2013, in San Francisco . The submission package for the...

Read More

Alla Chem, LLC Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection

August 5, 2013 — AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl – July 25, 2013 – Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C...

Read More